Quanterix completed the acquisition of Akoya Biosciences for $127 million, integrating spatial biology and tissue testing technologies to streamline liquid biopsy biomarker discovery and implementation. Simultaneously, Revolution Medicines partnered with AI-driven biotech Iambic Therapeutics to leverage NeuralPLexer, an AI model for protein-ligand interaction prediction, to accelerate oncology drug discovery. These collaborations underscore a trend of combining advanced molecular profiling and AI platforms to expand precision medicine capabilities across cancer and genetic diseases.